Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical oral investigations"
DOI: 10.1007/s00784-022-04393-1
Abstract: BACKGROUND Chronic Graft-versus-Host Disease (cGVHD) can impact quality of life, especially in patients with oral involvement. Half of the patients with cGVHD do not respond to first-line therapy with corticosteroids and calcineurin inhibitors. Ruxolitinib is… read more here.
Keywords: response; oral mucosa; oral involvement; ruxolitinib oral ... See more keywords